

# Ted M Burns

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10529370/publications.pdf>

Version: 2024-02-01

79  
papers

4,297  
citations

136740

32  
h-index

114278

63  
g-index

81  
all docs

81  
docs citations

81  
times ranked

2833  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. <i>Lancet Neurology</i> , The, 2017, 16, 976-986.	4.9	472
2	Myasthenia gravis. <i>Nature Reviews Disease Primers</i> , 2019, 5, 30.	18.1	421
3	The MG Composite. <i>Neurology</i> , 2010, 74, 1434-1440.	1.5	195
4	Rituximab as treatment for anti-MuSK myasthenia gravis. <i>Neurology</i> , 2017, 89, 1069-1077.	1.5	185
5	Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. <i>Neurology</i> , 2019, 92, e2661-e2673.	1.5	169
6	Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. <i>Muscle and Nerve</i> , 2019, 60, 14-24.	1.0	162
7	Less is more, or almost as much: A 15-item quality-of-life instrument for myasthenia gravis. <i>Muscle and Nerve</i> , 2008, 38, 957-963.	1.0	149
8	An update on the classification and treatment of vasculitic neuropathy. <i>Lancet Neurology</i> , The, 2005, 4, 853-865.	4.9	136
9	Electrical impedance myography as a biomarker to assess ALS progression. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2012, 13, 439-445.	2.3	125
10	Recommendations for myasthenia gravis clinical trials. <i>Muscle and Nerve</i> , 2012, 45, 909-917.	1.0	122
11	Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. <i>Neurology</i> , 2020, 95, e59-e69.	1.5	119
12	Mycophenolate mofetil in AChR antibody-positive myasthenia gravis: Outcomes in 102 patients. <i>Muscle and Nerve</i> , 2010, 41, 593-598.	1.0	109
13	A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. <i>Neurology</i> , 2016, 87, 57-64.	1.5	106
14	Construction of an efficient evaluative instrument for Myasthenia Gravis: The MG composite. <i>Muscle and Nerve</i> , 2008, 38, 1553-1562.	1.0	105
15	MG-ADL: Still a relevant outcome measure. <i>Muscle and Nerve</i> , 2011, 44, 727-731.	1.0	96
16	Quality of life and measures of quality of life in patients with neuromuscular disorders. <i>Muscle and Nerve</i> , 2012, 46, 9-25.	1.0	96
17	Guillain-Barré Syndrome. <i>Seminars in Neurology</i> , 2008, 28, 152-167.	0.5	93
18	Neurosarcoidosis. <i>Archives of Neurology</i> , 2003, 60, 1166.	4.9	89

#	ARTICLE	IF	CITATIONS
19	The MGâ€œQOL15 for following the healthâ€œrelated quality of life of patients with myasthenia gravis. Muscle and Nerve, 2011, 43, 14-18.	1.0	86
20	International clinimetric evaluation of the MGâ€œQOL15, resulting in slight revision and subsequent validation of the MGâ€œQOL15r. Muscle and Nerve, 2016, 54, 1015-1022.	1.0	85
21	Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?. Muscle and Nerve, 2014, 49, 483-486.	1.0	73
22	Construct and concurrent validation of the MGâ€œQOL15 in the practice setting. Muscle and Nerve, 2010, 41, 219-226.	1.0	69
23	Oculobulbar involvement is typical with Lambert-Eaton Myasthenic Syndrome. Annals of Neurology, 2003, 53, 270-273.	2.8	62
24	Electrical impedance myography correlates with standard measures of Als severity. Muscle and Nerve, 2014, 49, 441-443.	1.0	61
25	Adynamic ileus in severe Guillain-BarrÃ© syndrome. Muscle and Nerve, 2001, 24, 963-965.	1.0	59
26	Crossâ€œsectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment. Muscle and Nerve, 2019, 60, 707-715.	1.0	56
27	Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. Muscle and Nerve, 2019, 59, 404-410.	1.0	56
28	Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. Neurology, 2022, 98, .	1.5	51
29	History of outcome measures for myasthenia gravis. Muscle and Nerve, 2010, 42, 5-13.	1.0	48
30	Vasculitic Neuropathies. Neurologic Clinics, 2007, 25, 89-113.	0.8	45
31	Neuroleukemiosis: Case report of leukemic nerve infiltration in acute lymphoblastic leukemia. Muscle and Nerve, 2008, 38, 1196-1200.	1.0	43
32	Neuroendocrine lung tumors and disorders of the neuromuscular junction. Neurology, 1999, 52, 1490-1490.	1.5	35
33	Myasthenia Gravis. Seminars in Neurology, 2015, 35, 327-339.	0.5	34
34	The Evaluation of Polyneuropathies. Neurology, 2011, 76, S6-13.	1.5	32
35	Clinical versus quantitative vibration assessment: improving clinical performance. Journal of the Peripheral Nervous System, 2002, 7, 112-117.	1.4	26
36	The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice. Annals of the New York Academy of Sciences, 2012, 1274, 99-106.	1.8	26

#	ARTICLE	IF	CITATIONS
37	Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis. <i>Muscle and Nerve</i> , 2015, 52, 211-215.	1.0	24
38	Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. <i>Muscle and Nerve</i> , 2016, 53, 165-168.	1.0	24
39	Gasoline sniffing multifocal neuropathy. <i>Pediatric Neurology</i> , 2001, 25, 419-421.	1.0	19
40	Clinical applications of therapeutic apheresis. <i>Journal of Clinical Apheresis</i> , 2010, 25, 250-264.	0.7	19
41	The forecast for podcasts: Sunny skies but not necessarily with clear visibility. <i>Neurology</i> , 2007, 68, E19-E20.	1.5	18
42	Psychometric evaluation of the myasthenia gravis composite using rasch analysis. <i>Muscle and Nerve</i> , 2012, 45, 820-825.	1.0	18
43	The modified rankin scale to assess disability in myasthenia gravis: Comparing with other tools. <i>Muscle and Nerve</i> , 2014, 50, 501-507.	1.0	18
44	Two steps forward, one step back: Mycophenolate mofetil treatment for myasthenia gravis in the united states. <i>Muscle and Nerve</i> , 2015, 51, 635-637.	1.0	18
45	Novel myelin protein zero mutation (Arg36Trp) in a patient with acute onset painful neuropathy. <i>Neuromuscular Disorders</i> , 2006, 16, 308-310.	0.3	17
46	Brazilian cross-cultural translation and adaptation of the "Questionnaire of Life Quality Specific for Myasthenia Gravis - 15 items". <i>Arquivos De Neuro-Psiquiatria</i> , 2013, 71, 955-958.	0.3	17
47	Construction and validation of the chronic acquired polyneuropathy patient-reported index (CAPâ€PRI): A disease-specific, health-related quality-of-life instrument. <i>Muscle and Nerve</i> , 2016, 54, 9-17.	1.0	17
48	Construction and validation of a novel disease-specific quality-of-life instrument for patients with primary antibody deficiency disease (PADQOL-16). <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 2007-2010.e8.	1.5	17
49	Chronic Inflammatory Demyelinating Polyradiculoneuropathy. <i>Archives of Neurology</i> , 2004, 61, 973.	4.9	16
50	Current Therapeutic Strategies for Patients With Polyneuropathies Secondary to Inherited Metabolic Disorders. <i>Mayo Clinic Proceedings</i> , 2003, 78, 858-868.	1.4	15
51	Stiff person syndrome does not always occur with maternal passive transfer of GAD65 antibodies. <i>Neurology</i> , 2005, 64, 399-400.	1.5	13
52	The Evaluation of Chronic Axonal Polyneuropathies. <i>Seminars in Neurology</i> , 2008, 28, 133-151.	0.5	13
53	Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis. <i>EMBO Molecular Medicine</i> , 2021, 13, e12595.	3.3	13
54	The best of both worlds: Using patient-reported plus physician-scored measures during the evaluation of myasthenia gravis. <i>Muscle and Nerve</i> , 2016, 53, 3-4.	1.0	12

#	ARTICLE	IF	CITATIONS
55	The oculobulbar facial respiratory score is a tool to assess bulbar function in myasthenia gravis patients. <i>Muscle and Nerve</i> , 2011, 43, 329-334.	1.0	11
56	Pearls and Oysters: Evaluation of peripheral neuropathies. <i>Neurology</i> , 2009, 72, e28-31.	1.5	10
57	A step forward for stiff-person syndrome. <i>Lancet, The</i> , 2005, 365, 1365-1367.	6.3	9
58	Quality of life measures for myasthenia gravis and evaluation of non-motor symptoms. <i>Clinical and Experimental Neuroimmunology</i> , 2015, 6, 32-39.	0.5	9
59	SUNCT headaches after ipsilateral ophthalmic-distribution zoster. <i>Journal of the Neurological Sciences</i> , 2016, 366, 207-208.	0.3	8
60	Investigation of the psychometric properties of the inclusion body myositis functional rating scale with rasch analysis. <i>Muscle and Nerve</i> , 2019, 60, 161-168.	1.0	8
61	A crisis in <sc>US</sc> drug pricing: Consequences for patients with neuromuscular diseases, physicians and society, part 1. <i>Muscle and Nerve</i> , 2020, 62, 567-572.	1.0	7
62	Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy. <i>Neurology</i> , 2018, 90, e2034-e2041.	1.5	6
63	Chronic Acquired Polyneuropathy Patient Reported Index (CAPPRI) in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 247-252.	1.4	5
64	A crisis in <sc>US</sc> drug pricing: Consequences for patients with neuromuscular diseases, physicians, and society, part 2. <i>Muscle and Nerve</i> , 2020, 62, 573-578.	1.0	5
65	Clinical outcome assessments: The "Rasch" for improved accuracy. <i>Muscle and Nerve</i> , 2018, 58, 327-329.	1.0	4
66	The Adverse Event Unit (AEU): A novel metric to measure the burden of treatment adverse events. <i>PLoS ONE</i> , 2022, 17, e0262109.	1.1	3
67	More than meets the eye: The benefits of listening closely to what our patients with myasthenia gravis are telling us. <i>Muscle and Nerve</i> , 2012, 46, 153-154.	1.0	1
68	Reply. <i>Muscle and Nerve</i> , 2013, 47, 145-146.	1.0	1
69	Using disease-specific, patient-reported measures in everyday clinic. <i>Neurology</i> , 2016, 87, 858-859.	1.5	1
70	Reply. <i>Muscle and Nerve</i> , 2017, 55, 138-140.	1.0	1
71	On being sick. <i>Neurology</i> , 2017, 89, 414-416.	1.5	1
72	Adynamic ileus in severe Guillain-Barré syndrome. <i>Muscle and Nerve</i> , 2001, 24, 963-965.	1.0	1

#	ARTICLE	IF	CITATIONS
73	Peripheral Neuropathies in Infants and Children: Polyneuropathies, Mononeuropathies, Plexopathies, and Radiculopathies. , 2005, , 2707-2753.		0
74	Clinical Neurophysiology of Pediatric Polyneuropathies. , 2006, , 645-686.		0
75	Neuromuscular Disorders. Seminars in Neurology, 2008, 28, 131-132.	0.5	0
76	Case of the month: Leukemic nerve infiltration. Muscle and Nerve, 2009, 39, 413-414.	1.0	0
77	Estimating and managing fatigue for our patients: Are we measuring up?. Muscle and Nerve, 2018, 58, 182-183.	1.0	0
78	Autonomic Testing in Childhood. , 2006, , 687-712.		0
79	Rising Drug Costs for Neurologic Diseases. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 1392-1406.	0.4	0